← Back to Screener
Coya Therapeutics, Inc. Common Stock (COYA)
Price$4.42
Value ScoreC
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-40.03%
Price vs S&P 500 (4W)7.55%
VGM Score51.47
Market Capitalization$103.68M
All Metrics
Book Value / Share (Quarterly)$2.09
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.60
Price vs S&P 500 (YTD)-31.95%
Net Profit Margin (TTM)-266.11%
EPS (TTM)$-1.15
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-1.15
EPS (Annual)$-1.27
ROI (Annual)-49.33%
Cash / Share (Quarterly)$2.16
Revenue Growth QoQ (YoY)-2.61%
ROA (Last FY)-42.49%
Revenue Growth TTM (YoY)115.44%
EBITD / Share (TTM)$-1.24
ROE (5Y Avg)-50.50%
Operating Margin (TTM)-283.64%
Cash Flow / Share (Annual)$-0.51
P/B Ratio2.12x
P/B Ratio (Quarterly)1.89x
Net Income / Employee (Annual)$-2,653,300
EV / Revenue (TTM)6.67x
Net Interest Coverage (TTM)-17.25x
ROA (TTM)-50.09%
EPS Incl Extra (Annual)$-1.27
Current Ratio (Annual)8.50x
Quick Ratio (Quarterly)14.30x
3-Month Avg Trading Volume0.15M
52-Week Price Return-23.40%
Revenue / Employee (TTM)$992,400
Tangible BV / Share (Quarterly)$1.01
P/S Ratio (Annual)13.05x
Asset Turnover (Annual)0.16x
52-Week High$7.75
EPS Excl Extra (Annual)$-1.27
26-Week Price Return-32.10%
Quick Ratio (Annual)7.97x
13-Week Price Return-6.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.02x
Enterprise Value$52.96M
Asset Turnover (TTM)0.19x
Revenue / Employee (Annual)$993,200
Pretax Margin (Annual)-267.10%
Cash / Share (Annual)$2.24
3-Month Return Std Dev67.42%
Net Income / Employee (TTM)$-2,640,800
ROE (Last FY)-49.33%
EPS Basic Excl Extra (Annual)$-1.27
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.15
ROI (TTM)-57.26%
P/S Ratio (TTM)13.06x
Revenue / Share (Annual)$0.47
Tangible BV / Share (Annual)$-0.84
Price vs S&P 500 (52W)-47.76%
Year-to-Date Return-23.79%
5-Day Price Return-9.98%
EPS Normalized (Annual)$-1.27
ROA (5Y Avg)-68.64%
Net Profit Margin (Annual)-267.14%
Month-to-Date Return-8.30%
Cash Flow / Share (TTM)$-1.22
EBITD / Share (Annual)$-1.35
Operating Margin (Annual)-283.87%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.50%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.15
P/TBV (Quarterly)5.01x
P/B Ratio (Annual)2.82x
Pretax Margin (TTM)-266.07%
Book Value / Share (Annual)$2.06
Price vs S&P 500 (13W)-15.01%
Beta0.69x
Revenue / Share (TTM)$0.35
ROE (TTM)-57.26%
52-Week Low$3.71
vGradeC
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.32est. -0.42
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.15
4.15
4.15
4.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
COYACoya Therapeutics, Inc. Common Stock | C | B | C | $4.42 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Coya Therapeutics is a clinical-stage biotech company developing regulatory T cell therapies for neurodegenerative, autoimmune, and metabolic diseases. The company's proprietary multi-modality platform modulates Treg function to address multiple disease indications.